A look at a growing wave of US doctors and telehealth startups prescribing ketamine online, aided by looser federal rules on prescribing controlled substances
People can take the drug at home, thanks to federal action during the pandemic. Some experts worry it's now too easy to get.
Context & Ripple Effects
Online ketamine is the latest extension of a playbook regulators opened during the pandemic, when federal rules relaxed limits on prescribing controlled substances via telehealth. The same loosened rules already drew scrutiny when startups like Cerebral and Done used them to push stimulant prescriptions through 30-minute online evaluations with pressure on clinicians.
The category has a longer arc: experts flagged public-health risks at direct-to-consumer prescription sites like Hims back in 2019, and just last month the Wall Street Journal reported telehealth companies running social media ads promoting drugs for unapproved uses while omitting risks. Ketamine-at-home sits at the intersection of both patterns — a powerful drug delivered through a channel built for convenience.
First-order effects
- Patients can now obtain ketamine for at-home use through online doctor consultations, expanding access well beyond clinics that previously administered it.
- The doctors and telehealth startups doing the prescribing take on immediate liability exposure, since some experts already warn the drug is too easy to get.
Second-order effects
- Regulators face pressure to revisit the pandemic-era prescribing flexibilities before they lapse, following the pattern set when Cerebral and Done's stimulant practices triggered investigations.
- Telehealth operators marketing off-label uses — as reported in the recent ad-coverage — gain a new high-margin product line, forcing competitors to decide whether to match the offering or differentiate on clinical safeguards.
Third-order effects
- If the ketamine wave follows the stimulant precedent, the likely endpoint is a durable split in telehealth regulation: stricter oversight of controlled substances versus lighter-touch rules for ordinary prescriptions, reshaping which drugs DTC platforms can build businesses around.
The trend: Direct-to-consumer telehealth is steadily pushing higher-risk prescriptions online, with each new drug category testing how far the pandemic-era rules will stretch before regulators pull them back.